Surgery Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Promoter hypermethylation mediates downregulation of thiamine receptor slc19a3 in gastric cancer
Tumor Biology, 10/12/09

Liua X et al. – SLC19A3 was epigenetically downregulated in gastric cancer. Methylation of SLC19A3 promoter could be a novel biomarker for early gastric cancer development

Methods

Promoter hypermethylation used to define novel TSGs and identify biomarkers for cancer diagnosis
SLC19A3 expression downregulated in gastric cancer cell lines (71%, 5/7) and restored after pharmacological demethylation

Results

SLC19A3 (solute carrier family 19, member 3) found to be such a biomarker
Hypermethylation of SLC19A3 promoter detected in gastric cancer cell lines (57%, 4/7), primary gastric carcinoma tissues (51%, 52/101) and precancerous lesion (intestinal metaplasia) tissues (32%, 8/25)
Exogenous SLC19A3 expression caused growth inhibition of gastric cancer cells